199 related articles for article (PubMed ID: 28412731)
1. C-terminal binding protein-2 promotes cell proliferation and migration in breast cancer via suppression of p16INK4A.
Yang X; Sun Y; Li H; Shao Y; Zhao D; Yu W; Fu J
Oncotarget; 2017 Apr; 8(16):26154-26168. PubMed ID: 28412731
[TBL] [Abstract][Full Text] [Related]
2. High expression and prognostic role of CAP1 and CtBP2 in breast carcinoma: associated with E-cadherin and cell proliferation.
Liu X; Yao N; Qian J; Huang H
Med Oncol; 2014 Mar; 31(3):878. PubMed ID: 24522810
[TBL] [Abstract][Full Text] [Related]
3. CtBP2 contributes to malignant development of human esophageal squamous cell carcinoma by regulation of p16INK4A.
Guan C; Shi H; Wang H; Zhang J; Ni W; Chen B; Hou S; Yang X; Shen A; Ni R
J Cell Biochem; 2013 Jun; 114(6):1343-54. PubMed ID: 23255392
[TBL] [Abstract][Full Text] [Related]
4. CtBP2 overexpression promotes tumor cell proliferation and invasion in gastric cancer and is associated with poor prognosis.
Dai F; Xuan Y; Jin JJ; Yu S; Long ZW; Cai H; Liu XW; Zhou Y; Wang YN; Chen Z; Huang H
Oncotarget; 2017 Apr; 8(17):28736-28749. PubMed ID: 28404932
[TBL] [Abstract][Full Text] [Related]
5. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration.
Wang Y; Liu F; Mao F; Hang Q; Huang X; He S; Wang Y; Cheng C; Wang H; Xu G; Zhang T; Shen A
J Biol Chem; 2013 Mar; 288(13):9028-34. PubMed ID: 23393140
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of C-terminal binding protein 2 (CtBP2) inhibits proliferation, migration, and invasion of human SHSY5Y cells in vitro.
Nan J; Guan S; Jin X; Jian Z; Linshan F; Jun G
Neurosci Lett; 2017 Apr; 647():104-109. PubMed ID: 28179207
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer.
Liu Y; Du Y; Hu X; Zhao L; Xia W
BMC Cancer; 2018 Apr; 18(1):367. PubMed ID: 29614984
[TBL] [Abstract][Full Text] [Related]
8. CtBP2 promotes proliferation and reduces drug sensitivity in non-small cell lung cancer via the Wnt/β-catenin pathway.
Wang DP; Gu LL; Xue Q; Chen H; Mao GX
Neoplasma; 2018 Nov; 65(6):888-897. PubMed ID: 30334447
[TBL] [Abstract][Full Text] [Related]
9. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.
Birts CN; Harding R; Soosaipillai G; Halder T; Azim-Araghi A; Darley M; Cutress RI; Bateman AC; Blaydes JP
Biol Cell; 2010 Jan; 103(1):1-19. PubMed ID: 20964627
[TBL] [Abstract][Full Text] [Related]
10. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
11. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P
Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884
[TBL] [Abstract][Full Text] [Related]
12. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Li J; Guo Y; Duan L; Hu X; Zhang X; Hu J; Huang L; He R; Hu Z; Luo W; Tan T; Huang R; Liao D; Zhu YS; Luo DX
Oncotarget; 2017 May; 8(20):33694-33703. PubMed ID: 28402270
[TBL] [Abstract][Full Text] [Related]
13. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
14. CtBP2 interacts with ZBTB18 to promote malignancy of glioblastoma.
Chen L; Wang L; Qin J; Wei DS
Life Sci; 2020 Dec; 262():118477. PubMed ID: 32971103
[TBL] [Abstract][Full Text] [Related]
15. Citron kinase (CIT-K) promotes aggressiveness and tumorigenesis of breast cancer cells in vitro and in vivo: preliminary study of the underlying mechanism.
Meng D; Yu Q; Feng L; Luo M; Shao S; Huang S; Wang G; Jing X; Tong Z; Zhao X; Liu R
Clin Transl Oncol; 2019 Jul; 21(7):910-923. PubMed ID: 30565087
[TBL] [Abstract][Full Text] [Related]
16. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
17. CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelial-mesenchymal transition in hepatocellular carcinoma.
Zheng X; Song T; Dou C; Jia Y; Liu Q
Oncotarget; 2015 Feb; 6(6):3752-69. PubMed ID: 25686837
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
19. Amyloid-β precursor protein promotes cell proliferation and motility of advanced breast cancer.
Lim S; Yoo BK; Kim HS; Gilmore HL; Lee Y; Lee HP; Kim SJ; Letterio J; Lee HG
BMC Cancer; 2014 Dec; 14():928. PubMed ID: 25491510
[TBL] [Abstract][Full Text] [Related]
20. Low spinophilin expression enhances aggressive biological behavior of breast cancer.
Schwarzenbacher D; Stiegelbauer V; Deutsch A; Ress AL; Aigelsreiter A; Schauer S; Wagner K; Langsenlehner T; Resel M; Gerger A; Ling H; Ivan C; Calin GA; Hoefler G; Rinner B; Pichler M
Oncotarget; 2015 May; 6(13):11191-202. PubMed ID: 25857299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
